Streetbeat News

Products Services

SANA

Sana Biotechnology, Inc. (NASDAQ:SANA) shares rose after the FDA cleared its IND application for SC262, a study for patients with relapsed or refractory B-cell malignancies. This clearance follows a previous FDA clearance for SC291 for lupus nephritis and related conditions. The company anticipates presenting data from multiple studies, including SC262, later in the year. SANA's stock price increased by 2.24% to $5.01.

Portfolio Pulse from Nabaparna Bhattacharya

January 05, 2024 | 3:54 pm

AAPL

GOOGL

META

MSFT

NVDA

QQQ

SPY

TSLA

The Market Clubhouse Morning Memo provides daily trading levels for SPY, QQQ, AAPL, MSFT, TSLA, GOOGL, META, and NVDA based on a proprietary formula considering price, volume, and options flow. The memo outlines potential bullish and bearish price targets for each asset and advises traders to monitor these stocks closely for breakouts or reversals. The release of the Non-Farm Payrolls report is expected to significantly influence market sentiment and volatility. The memo is part of the Market Clubhouse membership, which offers daily market analysis, a watch list, and real-time trading mentorship by a professional trader known as RIPS.

Portfolio Pulse from RIPS

January 05, 2024 | 3:46 pm

CRWD

CrowdStrike Holdings Inc (NASDAQ:CRWD) is named as the 'Top Pick For 2024' in cybersecurity by Oppenheimer analyst Ittai Kidron, who maintains an Outperform rating and raises the price target from $240 to $300. The company benefits from high cybersecurity spending, attractive cross-sell opportunities with Falcon Data Protection, ARR/NRR expansion, and leveraging partnerships. Despite a strong performance in 2023, further upside is expected in fiscal 2025.

Portfolio Pulse from Priya Nigam

January 05, 2024 | 3:41 pm

NVO

A U.S. study found that Novo Nordisk's drugs Ozempic and Wegovy do not increase the risk of suicidal thoughts. Contrary to prior concerns, the study showed a lower incidence of such thoughts among users compared to other treatments. The study, funded by the U.S. National Institutes of Health and published in 'Nature,' analyzed data from over 1.8 million patients. Semaglutide, the active ingredient in both drugs, was linked to a significantly lower risk of suicidal ideations. Novo Nordisk's stock (NVO) was down 0.60% at $106.99 on the last check Friday.

Portfolio Pulse from Vandana Singh

January 05, 2024 | 3:41 pm

DRMA

Dermata Therapeutics Inc (NASDAQ:DRMA) stock rose after announcing a new patent in Japan for its DMT410 program for hyperhidrosis. The patent strengthens the company's IP and could support further development for additional skin conditions. The company's Spongilla technology enables topical delivery of botulinum toxin, avoiding injections. Phase 1 trials of DMT410 with BOTOX showed promising results for hyperhidrosis and aesthetic skin conditions. DRMA shares surged 31% to 80 cents.

Portfolio Pulse from Vandana Singh

January 05, 2024 | 3:40 pm

CVAC

GSK

CureVac N.V. (NASDAQ:CVAC) shares are rising after the company announced positive interim data from a Phase 2 study of its COVID-19 vaccine candidates developed with GSK Plc (NYSE:GSK). The study showed meaningful immune responses and favorable reactogenicity profiles at all tested doses. The vaccines use CureVac's second-generation mRNA technology and are part of a joint development program with GSK, which also includes a flu vaccine program.

Portfolio Pulse from Nabaparna Bhattacharya

January 05, 2024 | 3:31 pm

AZN

GRCL

AstraZeneca (NASDAQ:AZN) is set to acquire Gracell Biotechnologies Inc. (NASDAQ:GRCL) for up to $1.2 billion, an 86% premium over its pre-announcement share price. The deal offers hope for cash-strapped Chinese biotechs, as Gracell's shares surged 60.3% post-announcement. Gracell, which focuses on CAR-T cell therapy for cancer treatment, has been operating at a loss with its most advanced product still in phase 1 trials. The acquisition by AstraZeneca will bolster its cell therapy capabilities, taking over Gracell's technology and trials. However, the sector faces uncertainty due to an FDA investigation into potential risks associated with CAR-T therapies.

Portfolio Pulse from The Bamboo Works

January 05, 2024 | 3:26 pm

GOOG

GOOGL

A Reddit user used Stability AI's Stable Diffusion to create a realistic image of a non-existent woman with a fake passport, raising concerns about AI's potential to forge identities. The incident reflects growing issues with AI misuse, as seen with Scarlett Johansson's lawsuit and fake images in a New Jersey high school. Google has developed a tool to detect AI-generated photos, aiming to mitigate such risks.

Portfolio Pulse from Rounak Jain

January 05, 2024 | 3:18 pm

LUCY

Innovative Eyewear has entered into a license agreement and reached a settlement regarding several IngenioSpec smart eyewear patents. This agreement resolves previous disputes and grants Innovative Eyewear access to important smart eyewear technology.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 3:06 pm

INGN

Citron Research has declared Inogen's portable oxygen concentrator (POC) as the best product on the market, based on a comprehensive study by the NCOA involving over 1,000 hours and 600 surveys with expert consultation.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 2:58 pm